3 Apr 2008

Technology Transfer Services

Long time ago, technology was very limited to certain people, so that not all people could take an advantages. Moreover, technology in the past was very private and not commercialized like nowadays. However, since last 7 decades ago, Yissum has successfully changed those dogmas. Yissum, the Technology Transfer University of the Hebrew University of Jerusalem, aims to promote the transfer of Hebrew University technology for the benefit of society, while maximizing returns to support research, education and scientific excellence.

Yissum, which also known as Center for Nanoscience and Nanotechnolog actually was founded in 1964 by Hebrew University of Jerusalem to protect the Hebrew University's intellectual property and commercialize it. $1 Billion in annual sales are generated by products based on Hebrew University technologies licensed out by Yissum. Ranked among the top technology transfer companies in the world, Yissum has registered 5500 patents covering 1600 inventions; licensed out 480 technologies and spun out 65 companies. Moreover, since 1964, Yissum is one of the first Technology Transfer Services companies worldwide – second only to the Weizmann Institute’s Yeda, founded in 1959, and many years senior to most American universities – which began their Technology Transfer Services activities following the Baye-Dole Act of 1980; European universities, which typically began these activities in the 1990’s and Japan, which only began in 1998.

In 2005, Yissum, based on the technology of Professor Chezy Barenholz has successfully floated the first Initial Public Offerring of its own on the Tel Aviv stock exchange. The company now has $10 million in the bank and is in clinical trials with its influenza vaccine. This is not the first commercial success for Prof. Barenholz, who is also the developer of Doxil™, sold by Johnson & Johnson (through its acquisition of Alza) in the United States and Schering Plough (under the trade name Caelyx™) internationally. Doxil™ enjoyed worldwide sales of over $400 million in 2005.

The submission to the NIH of a grant application by Prof. Raymond Kaempfer lately also has become the one proud of Yissum which sponsor it through the creation of Atox Bio Inc. As a matter of fact, Prof. Raymond Kaempfer successfully received US$ 5.6 million for the biodefence applications of super-antigens. Yissum continues to support AtoxBio as it develops other applications of Prof Kaempfer’s technology.

Another proof from the Yissum success is from BioCancell Inc. Biocancell Inc was highlighted in last year’s report, successfully raised over US$3 million from private investors and the Hebrew University’s pension fund (as an independent investor), and successfully began clinical trials with its H19-based therapy in patients suffering from bladder cancer.

Based on the change of management inside Yissum in 2005, Yissum has announced some organizational changes aimed at providing the university’s researchers with better, more focused service.

0 komentar:


Blog Archive

What's up doc?

Tebak Hari Lahir

When were you born?

Powered by Blogger.



Design by Blogger Buster | Distributed by Blogging Tips